SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Mocha Jet, Drugdoctor, RizZo, lasers, John_Langston, IB_
Search This Board:
Last Post: 8/1/2015 2:18:46 AM - Followers: 682 - Board type: Free - Posts Today: 2

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


Apr 21, 2015
Elite Pharmaceuticals Announces Launch Of Generic Hydroxyzine Tablets
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=76601&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


Feb 17, 2015
Elite Pharmaceuticals Provides Guidance On Phase III Study For ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=75450&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jan, 15 2015
Elite Pharmaceuticals Announces First Shipment Of Generic Isradipine Capsules
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=74835&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:

Third Quarter ending December 31, 2014
♦  Consolidated revenues for the third quarter of Fiscal 2015 continued their upward trend, rising to $1.4 million, an increase of approximately 8.5% over consolidated revenues for the second quarter of Fiscal 2015. The third quarter revenues for this year were $0.3 million below revenues reported for the third quarter of the prior fiscal year due to a one-time $0.6 million milestone that occurred in the prior year third quarter. Development of our proprietary abuse-deterrent opioid technology continues to be Elite's top priority. During the quarter, Elite invested an additional $2.3 million in clinical trials and other product development activities.

Highlights for the third quarter
♦  As of December 31, our working capital was $8.9 million, including cash of $8.3 million.
♦  Isradipine was recently launched, and we expect to introduce Hydroxyzine and Dantrolene in the near-term.
♦  We're a penny stock company with eyes on NASDAQ; we need to be Sarbanes Oxley compliant. So we are evaluating the gaps that we have by hiring consultants and external consultants in order to evaluate the checks and      balances we have in order for us to get there.
♦  We are creating infrastructure in our facilities with expanding the facilities and adding new equipment and upgrading the current equipment in order to support our (Eli-200) product launch.
2014 was our best year, 2015 will be the year we file our first ART product, and Q1 2016 will be the year we launch our first ART product and hopefully will be the year we will be on NASDAQ.

Nine-Month Period Ending December 31, 2014
♦  Revenues for the nine months ending December 31, 2014 were $3.8 million, an increase of 6% over revenues for the comparable period of the prior year, even with the one-time milestone being included in the prior year revenues. The increase in revenues is due to the continued growth and expansion of Elite's generic product lines.
♦  During the first nine months of the fiscal year, Elite has invested a total of $9.9 million in product development, including successful completion of the human abuse liability study for ELI-200.
Financials:

 

Products:
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: dianne@elitepharma.com

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 

                                             ELTP Potential Share Price in Relation to Percentage of Pain Market Captured



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
Wiki
ELTP News: Amended Statement of Beneficial Ownership (sc 13d/a) 07/16/2015 04:52:46 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 06/22/2015 02:47:10 PM
ELTP News: Annual Report (10-k) 06/15/2015 04:36:59 PM
ELTP News: Undervalued and Underexposed NYSE-MKT Stock to be Profiled by Large Media Group and four brief reports 06/15/2015 07:00:00 AM
ELTP News: Current Report Filing (8-k) 06/09/2015 01:41:17 PM
PostSubject
#160330  Sticky Note Dianne Will urged me to file SEC Complaint WeeZuhl 07/25/15 09:38:13 AM
#156597  Sticky Note A few more additional FACTS about the Actavis/Epic/Elite Couch 06/11/15 08:13:37 PM
#156231  Sticky Note FOR THOSE WANTING A DEEPER UNDERSTANDING OF WHY Couch 06/09/15 08:10:52 PM
#148487  Sticky Note Ya-don't-say???-Trial-record-1 of-66-for:-eli-200 Drugdoctor 03/21/15 11:04:27 AM
#142585  Sticky Note Great info! This is the beginning of a Dr Speculator Ninja 01/29/15 02:56:03 PM
#106205  Sticky Note Elite’s 1st Generation Triple Patents and their Purpose lasers 04/30/14 08:50:54 AM
#160889   SCHH there was a pharmacy robbed in the Jimmy Joe 08/01/15 02:18:46 AM
#160888   Sorry didn't know this was stressing anyone out. richme 08/01/15 01:59:23 AM
#160887   there is big trouble in "river city" SCHH 07/31/15 11:18:35 PM
#160886   5% hype and 95% stress out? YJ4LIFE 07/31/15 10:45:19 PM
#160885   It will be interesting to see how the mrwrn2010 07/31/15 10:44:53 PM
#160884   I like cheeseburgers....I see the trial stopped recruiting. Pharma Sleuth 07/31/15 10:30:14 PM
#160883   You mean the millionaire/billionaire bit isn't fooling anyone? richme 07/31/15 10:20:03 PM
#160882   My opinion and few will deny; the logistics richme 07/31/15 10:01:32 PM
#160881   Wish I would've sold my ELTP shares at mrwrn2010 07/31/15 09:45:03 PM
#160880   Oppps wrong again! Doc.. it is what is Jimmy Joe 07/31/15 09:30:02 PM
#160879   Yes I know sell the shares by .125 Couch 07/31/15 09:17:29 PM
#160878   Buy the dips. NASDAQ2020 07/31/15 08:48:13 PM
#160877   Except for the fact that it's higher green Couch 07/31/15 08:26:08 PM
#160876   No, it isn't. mrwrn2010 07/31/15 06:14:12 PM
#160875   No that is just nonsense dr_lowenstein 07/31/15 06:13:45 PM
#160874   Green is good ! why not? snupoled 07/31/15 05:59:05 PM
#160873   Nah also ran tech is what dose dumped mrwrn2010 07/31/15 05:48:03 PM
#160872   Yes, I know. Buy the cheapies while richme 07/31/15 05:46:33 PM
#160871   That was 17 months ago ! toybaby 07/31/15 05:43:47 PM
#160870   Oh it's OK - if you judge from Dr Speculator Ninja 07/31/15 05:42:14 PM
#160869   Try .74; hope that is more impressive! richme 07/31/15 05:40:04 PM
#160868   Weekly not bi-weekly. But then again the richme 07/31/15 05:38:43 PM
#160867   Now you are concerned about WEEKLY? OK. Usually Dr Speculator Ninja 07/31/15 05:31:35 PM
#160866   OH BOY $.01 drop WHAT A toybaby 07/31/15 05:23:00 PM
#160864   Or GREEN ! It's a stock. Dr Speculator Ninja 07/31/15 05:13:46 PM
#160863   You wait a few minutes and presto RED richme 07/31/15 05:08:57 PM
#160860   Elite is welcoming August with a bright outlook! Aqua 07/31/15 04:51:57 PM
#160859   I wish they would LEAVE already ... toybaby 07/31/15 04:49:47 PM
#160858   Maybe you should blame yourself for buying at Mazeppa 07/31/15 04:44:53 PM
#160857   .038 .051 .06 .125 .18 . 205 .236 Couch 07/31/15 04:29:38 PM
#160856   And .64, .35, .34, and .265; thanks for richme 07/31/15 04:26:56 PM
#160855   ELTP doesn't need luck. Someone needs a lot YJ4LIFE 07/31/15 04:24:35 PM
#160854   This study is ongoing, John_Langston 07/31/15 04:06:17 PM
#160853   Again, won't need it but thanks. Eli 200 Couch 07/31/15 04:02:50 PM
#160852   Eli 200 launch coming. John_Langston 07/31/15 04:00:58 PM
#160851   JL- I hope you were joking about buying mts 07/31/15 03:59:41 PM
#160850   I won't need luck. Eli 200 launch coming. Couch 07/31/15 03:56:38 PM
#160849   Elites ADT is coming and there is not Jimmy Joe 07/31/15 03:46:49 PM
#160848   good luck with that. You too. John_Langston 07/31/15 03:41:33 PM
#160847   Efficacy phase 3 recruitment has already finished- good Couch 07/31/15 03:31:22 PM
#160846   Guilty till proven innocent and even then we're toofun 07/31/15 03:30:57 PM
#160845   http://m.wesh.com/news/pharmacy-rejects-pain-prescription-for-4yearold-with-canc Thehustle 07/31/15 03:27:02 PM
#160844   ELTP chart with Bollinger Bands conix 07/31/15 03:00:39 PM
#160843   nah, just also ran technology dr_lowenstein 07/31/15 02:57:24 PM
#160842   ELI-200 NDA submission. Jimmy Joe 07/31/15 02:55:12 PM
#160841   Elites ADF technology: Jimmy Joe 07/31/15 02:49:39 PM
#160840   Awesome John_Langston 07/31/15 02:36:48 PM
#160839   Last PH III few days from completion. NASDAQ2020 07/31/15 02:35:30 PM
#160838   USPTO FdA , HAL study NASDAQ2020 07/31/15 02:32:18 PM
#160837   39¢ to high; it will be more like 1¢ John_Langston 07/31/15 02:30:30 PM
PostSubject